Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
Wednesday, July 31, 2024Roche announced today that the European Commission has approved Vabysmo for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion RVO is the third indication for Vabysmo in the European Union
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA
Wednesday, July 31, 2024PTC Therapeutics Inc announced today the submission of the sepiapterin NDA to the US FDA The NDA submission is for the treatment of pediatric and adult patients with phenylketonuria including the full spectrum of ages
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
Wednesday, July 31, 2024NeuroBo Pharmaceuticals Inc a clinicalstage biotechnology company focused on the transformation of cardiometabolic diseases today announced the signing of an exclusive license agreement providing MThera Pharma Co Ltd
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Wednesday, July 31, 2024Processa Pharmaceuticals Inc a clinicalstage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
Tuesday, July 30, 2024Enzolytics Inc announced today that it has entered into a year Collaboration Agreement with Elimus Ltd Elimus a Bulgarian company located in Sofia for the manufacturing development and marketing of new and existing nutraceutical
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Tuesday, July 30, 2024Syndax Pharmaceuticals a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
Tuesday, July 30, 2024Alpha Cognition a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders announces that the US Food and Drug Administration has granted approval for ZUNVEYL
BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial
Monday, July 29, 2024BerGenBio ASA a clinicalstage biopharmaceutical company developing novel selective AXL kinase inhibitors for severe unmet medical needs announced today that the independent Data and Safety Monitoring Board
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Monday, July 29, 2024GSK plc and Flagship Pioneering Flagship the bioplatform innovation company today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Saturday, July 27, 2024Ipsen announced today two positive opinions by the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP
